Abstract:Somatostatin receptors (SSTR) are expressed by many tumours especially those related to neuro-endocrine origin and molecular functional imaging of SSTR expression using radiolabelled somatostatin analogs have revolutionized imaging of patients with these group of malignancies. Coming a long way from the first radiolabelled somatostatin analog 123I-Tyr-3-octreotide, there has been significant developments in terms of radionuclides used, the ligands and somatostatin derivatives. 111In-Pentetreotide extensively employed for imaging NETs at the beginning has now been replaced by 68Ga-SSA based PET-CT. SSA-PET/CT performs superior to conventional imaging modalities and has evolved in the mainframe for NET imaging. The advantages were multiple: (i) superior spatial resolution of PET versus SPECT, (ii) quantitative capabilities of PET aiding in disease activity and treatment response monitoring with better precision, (iii) shorter scan time and (iv) less patient exposure to radiation. The modality is indicated for staging, detecting the primary in CUP-NETs, restaging, treatment planning (along with FDG: the concept of dual-tracer PET-CT) as well as treatment response evaluation and follow-up of NETs. SSA PET/CT has also been incorporated in the guidelines for imaging of Pheochromocytoma-Paraganglioma, Medullary carcinoma thyroid, Meningioma and Tumor induced osteomalacia. At present, there is rising interest on (a) 18F-labelled SSA, (b) 64Cu-labelled SSA, and (c) somatostatin antagonists. 18F offers excellent imaging properties, 64Cu makes delayed imaging feasible which has implications in dosimetry and SSTR antagonists bind with the SST receptors with high affinity and specificity, providing high contrast images with less background, which can be translated to theranostics effectively. SSTR have been demonstrated in non-neuroendocrine tumours as well in the peer-reviewed literature, with studies demonstrating the potential of SSA PET/CT in Neuroblastoma, Nasopharyngeal carcinoma, carcinoma prostate (neuroendocrine differentiation) and lymphoma. This review will focus on the currently available SSAs and their history, different SPECT/PET agents, SSTR antagonists, comparison between the various imaging tracers, and their utility in both neuroendocrine and non-neuroendocrine tumors.

Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies

Theranostics in Neuroendocrine Tumors

Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update

Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects

Somatostatin Receptor-Based Molecular Imaging and Therapy for Neuroendocrine Tumors.

Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and Alternatives

Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements

Molecular Imaging and Therapy for Neuroendocrine Tumors

Targeted radionuclide therapy: an emerging field in solid tumours

State-of-the-Art Hybrid Imaging of Neuroendocrine Neoplasms

Somatostatin receptor‐linked α‐particle therapy in neuroendocrine tumours

Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review

Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms

Peptide Receptor Radiotherapy Comes of Age

Radiolabeled Somatostatin Analogs for Cancer Imaging

Role of Ga-68 DOTANOC Positron Emission Tomography/ Computed Tomography Scan in Clinical Management of Patients with Neuroendocrine Tumors and its Correlation with Conventional Imaging- Experience in a Tertiary Care Center in India

The Impact of Somatostatin Receptor–Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis

Current and emerging strategies for the management of advanced/metastatic lung neuroendocrine tumors

Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management

Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms

Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023